Current Report Filing (8-k)
November 12 2020 - 5:08AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 11, 2020
Beyond
Air, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
|
|
000-38892
|
|
47-3812456
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
825
East Gate Blvd., Suite 320
Garden
City, NY 11530
(Address
of Principal Executive Office)
516-665-8200
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $.0001 per share
|
|
XAIR
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01. Other Events.
On
November 11, 2020, Beyond Air, Inc. (the “Company”) issued a press release (the “Press Release”) announcing
that it had submitted a premarket approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”)
for its LungFit™ PH to treat persistent pulmonary hypertension of the newborn. FDA guidelines allow for a 180-day review
period for a PMA. A copy of the Press Release is attached hereto and incorporated herein by reference in its entirety as Exhibit
99.1.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BEYOND
AIR, INC.
|
|
|
Date:
November 12, 2020
|
By:
|
/s/
Steven A. Lisi
|
|
|
Steven
A. Lisi
|
|
|
Chief
Executive Officer
|
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Apr 2024 to May 2024
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From May 2023 to May 2024